GSK's retrospective trial diversity study shows there's more work to do

What if the biopharma industry used epidemiology data, rather than the U.S. Census Bureau to build clinical trial rosters? GSK put the idea to the test in a 17-year retroactive study of clinical trial data from 495 trials, finding that there’s plenty of work to be done to ensure clinical research is representative of the patients who suffer from diseases.